Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$353 Mln
P/E Ratio
--
P/B Ratio
4.63
Industry P/E
--
Debt to Equity
0
ROE
-0.47 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
-1.27
CFO
A$-105.93 Mln
EBITDA
A$-98.22 Mln
Net Profit
A$-108.43 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Benitec Biopharma - ADR
| 8.67 | -14.80 | 28.39 | 104.24 | -25.59 | -41.98 | -41.82 |
|
BSE Sensex
| 2.39 | 4.18 | 4.86 | 8.78 | 11.89 | 20.62 | 11.13 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Benitec Biopharma - ADR
| 286.70 | 11.76 | -93.51 | -12.67 | -60.78 | -66.00 | -48.12 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is... developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. Benitec Biopharma Inc. was incorporated in 1995 and is headquartered in Hayward, California. Address: 3940 Trust Way, Hayward, CA, United States, 94545 Read more
Executive Chairman & CEO
Dr. Jerel A. Banks M.D., Ph.D.
Executive Chairman & CEO
Dr. Jerel A. Banks M.D., Ph.D.
Headquarters
Hayward, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Benitec Biopharma Inc - ADR stood at $ 82 Mln as on 31-Dec-24
The share price of Benitec Biopharma Inc - ADR is $13.73 (NASDAQ) as of 23-Apr-2025 14:03 EDT. Benitec Biopharma Inc - ADR has given a return of -25.59% in the last 3 years.
Benitec Biopharma Inc - ADR has a market capitalisation of $ 353 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Benitec Biopharma Inc - ADR is 4.63 times as on 22-Apr-2025, a 110% premium to its peers’ median range of 2.20 times.
Since, TTM earnings of Benitec Biopharma Inc - ADR is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Benitec Biopharma Inc - ADR and enter the required number of quantities and click on buy to purchase the shares of Benitec Biopharma Inc - ADR.
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. Benitec Biopharma Inc. was incorporated in 1995 and is headquartered in Hayward, California. Address: 3940 Trust Way, Hayward, CA, United States, 94545
The CEO & director of Dr. Jerel A. Banks M.D., Ph.D.. is Benitec Biopharma Inc - ADR, and CFO & Sr. VP is Dr. Jerel A. Banks M.D., Ph.D..
There is no promoter pledging in Benitec Biopharma Inc - ADR.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|
| Benitec Biopharma Inc. - ADR | Ratios |
|---|---|
|
Return on equity(%)
|
-34.77
|
|
Operating margin(%)
|
-404816.67
|
|
Net Margin(%)
|
-356916.67
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Benitec Biopharma Inc - ADR was $0 Mln.
$-0.06
(
